David S. McKinsey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
David S. McKinsey has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Joel P. McKinsey
Research Medical Center, Kansas City, MO
3 shared publicationsAlison Laufer Halpin
Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, GA; Commissioned Corps, U.S. Public Health Service, Rockville MD
1 shared publicationAlyssa Agard
Research Medical Center, Kansas City, MO
1 shared publicationBrianna Zellmer
Research Medical Center, Kansas City, MO
1 shared publicationCarolyn Gasser
Research Medical Center, Kansas City, MO
1 shared publicationCarrie Poteete
Research Medical Center, Kansas City, MO
1 shared publication
Latest Publications
- 1 September 2021
- Published by Elsevier in American Journal of Infection Control
- Vol. 49 (9) , 1183-1185
A comprehensive approach to ending an outbreak of rare bla gene-positive carbapenem-resistant Acinetobacter baumannii at a Community Hospital, Kansas City, MO, 2018
- 1 September 2021
- Published by Elsevier in American Journal of Infection Control
- Vol. 49 (9) , 1183-1185
A comprehensive approach to ending an outbreak of rare bla gene-positive carbapenem-resistant Acinetobacter baumannii at a Community Hospital, Kansas City, MO, 2018
- Open Access
- 28 May 2021
- Published by MDPI AG in Journal of Fungi
- Vol. 7 (6) , 429
Treatment and Prevention of Histoplasmosis in Adults Living with HIV
Histoplasmosis causes life-threatening disseminated infection in adult patients living with untreated HIV. Although disease incidence has declined dramatically in countries with access to antiretroviral therapy, histoplasmosis remains prevalent in many resource-limited regions. A high index of suspicion for histoplasmosis should be maintained in the setting of a febrile multisystem illness in severely immunosuppressed patients, particularly in persons with hemophagocytic lymphohistiocytosis. Preferred treatment regimens for initial therapy include liposomal amphotericin B for severe disease, or itraconazole for mild to moderate disease. Subsequently, itraconazole maintenance therapy should be administered for at least one year and then discontinued if CD4 count increases to ≥150 cells/µL. Antiretroviral therapy, which improves outcome when administered together with an antifungal agent, should be instituted immediately, as the risk of triggering Immune Reconstitution Syndrome is low. The major risk factor for relapsed infection is nonadherence. Itraconazole prophylaxis reduces risk for histoplasmosis in patients with CD4 counts <100/µL but is not associated with survival benefit and is primarily reserved for use in outbreaks. Although most patients with histoplasmosis have not had recognized high-risk exposures, avoidance of contact with bird or bat guano or inhalation of aerosolized soil in endemic regions may reduce risk. Adherence to effective antiretroviral therapy is the most important strategy for reducing the incidence of life-threatening histoplasmosis.
- 28 May 2021
- Published by MDPI AG in Journal of Fungi
- Vol. 7 (6) , 429
Open AccessTreatment and Prevention of Histoplasmosis in Adults Living with HIV
Histoplasmosis causes life-threatening disseminated infection in adult patients living with untreated HIV. Although disease incidence has declined dramatically in countries with access to antiretroviral therapy, histoplasmosis remains prevalent in many resource-limited regions. A high index of suspicion for histoplasmosis should be maintained in the setting of a febrile multisystem illness in severely immunosuppressed patients, particularly in persons with hemophagocytic lymphohistiocytosis. Preferred treatment regimens for initial therapy include liposomal amphotericin B for severe disease, or itraconazole for mild to moderate disease. Subsequently, itraconazole maintenance therapy should be administered for at least one year and then discontinued if CD4 count increases to ≥150 cells/µL. Antiretroviral therapy, which improves outcome when administered together with an antifungal agent, should be instituted immediately, as the risk of triggering Immune Reconstitution Syndrome is low. The major risk factor for relapsed infection is nonadherence. Itraconazole prophylaxis reduces risk for histoplasmosis in patients with CD4 counts <100/µL but is not associated with survival benefit and is primarily reserved for use in outbreaks. Although most patients with histoplasmosis have not had recognized high-risk exposures, avoidance of contact with bird or bat guano or inhalation of aerosolized soil in endemic regions may reduce risk. Adherence to effective antiretroviral therapy is the most important strategy for reducing the incidence of life-threatening histoplasmosis.
- 13 December 2011
- Published by Georg Thieme Verlag KG in Seminars in Respiratory and Critical Care Medicine
- Vol. 32 (06) , 735-744
Pulmonary Histoplasmosis
Pulmonary histoplasmosis is an important cause of morbidity in the United States. Several outbreaks of acute pulmonary histoplasmosis have been linked to potentially preventable environmental exposures. Progressive disseminated histoplasmosis, which is seen frequently in the growing population of immunocompromised hosts, often presents with prominent pulmonary manifestations and is more commonly encountered in hospitalized patients than acute, subacute, or chronic pulmonary histoplasmosis. A battery of diagnostic studies including serology, antigen, cytology/histopathology, and culture should be obtained in suspected cases of histoplasmosis. The yield of antigenuria detection is highest when the multiple body fluids are tested; the level of antigenuria correlates with severity of disease. Amphotericin B is the treatment of choice for severe pulmonary or disseminated histoplasmosis, and itraconazole is effective for mild to moderately severe infection. Posaconazole exhibits promise as a salvage agent. Antifungal prophylaxis is not routinely recommended for at-risk populations. Measures to minimize environmental contamination may reduce the risk of epidemic-type acute pulmonary histoplasmosis related to high-risk exposures.
- 13 December 2011
- Published by Georg Thieme Verlag KG in Seminars in Respiratory and Critical Care Medicine
- Vol. 32 (06) , 735-744
Pulmonary Histoplasmosis
Pulmonary histoplasmosis is an important cause of morbidity in the United States. Several outbreaks of acute pulmonary histoplasmosis have been linked to potentially preventable environmental exposures. Progressive disseminated histoplasmosis, which is seen frequently in the growing population of immunocompromised hosts, often presents with prominent pulmonary manifestations and is more commonly encountered in hospitalized patients than acute, subacute, or chronic pulmonary histoplasmosis. A battery of diagnostic studies including serology, antigen, cytology/histopathology, and culture should be obtained in suspected cases of histoplasmosis. The yield of antigenuria detection is highest when the multiple body fluids are tested; the level of antigenuria correlates with severity of disease. Amphotericin B is the treatment of choice for severe pulmonary or disseminated histoplasmosis, and itraconazole is effective for mild to moderately severe infection. Posaconazole exhibits promise as a salvage agent. Antifungal prophylaxis is not routinely recommended for at-risk populations. Measures to minimize environmental contamination may reduce the risk of epidemic-type acute pulmonary histoplasmosis related to high-risk exposures.
- 27 November 2009
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 66 (3) , 339-340
Extent of Interlaboratory discrepancies for polyclonal Histoplasma antigen Enzyme imunoassay (EIA) cannot be determined without a large split-sample study (reply)
- 27 November 2009
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 66 (3) , 339-340
Extent of Interlaboratory discrepancies for polyclonal Histoplasma antigen Enzyme imunoassay (EIA) cannot be determined without a large split-sample study (reply)
- 30 May 2008
- Published by Springer Nature in Current Fungal Infection Reports
- Vol. 2 (2) , 94-102
Diagnosis and management of histoplasmosis
- 30 May 2008
- Published by Springer Nature in Current Fungal Infection Reports
- Vol. 2 (2) , 94-102
Diagnosis and management of histoplasmosis